The strategic plan for the RMRCE is based on the program's past successes and those activities that have emerged as true and in many ways unique RMRCE strengths. These include: 1) establishment of nationally and internationally recognized expertise and research capabilities in understudied pathogens, especially Burkholderia and Coxiella;2) utilization of new BSL3 capabilities across the region, including the Rocky Mountain Regional Biocontainment Laboratory, 3) studies of only virulent Select Agents instead of model organisms;4) development of broad-platform technologies for therapeutics and vaccines;this includes cationic lipid DMA complex (CLDC) originally developed at Colorado State University which will be used by bacterial and viral research projects alike;5) highly integrated research projects;and 6) institution of region wide RMRCE leadership. These are the strengths and opportunities that the RMRCE will build on for the next 5 years. Additionally, the strategic plan takes into account NIAID mandated RCE activities that are in need of restructuring and refocusing under the RMRCE. Based on programmatic strengths the overall RMRCE structure (Figure 1) was developed to emphasize a robust and flexible research program that is directed at specific thematic areas important to the overall national effort in biodefense and emerging infectious diseases research, and that is supported by scientific cores designed to enhance research and facilitate product development. This structure and strategic plan also are aligned with the previously stated goals of this program. The details of the operation of the RMRCE and the individual components are described in the Action Plan (Section A-2.4) and the strengths and opportunities enabling this organizational structure are detailed in Sections A-2.1 and A-2.2. The thematic areas that from the basis of the RMRCE strategic plan are discussed in section A- 2.3.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI065357-06
Application #
8070330
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
6
Fiscal Year
2010
Total Cost
$562,089
Indirect Cost
Name
Colorado State University-Fort Collins
Department
Type
DUNS #
785979618
City
Fort Collins
State
CO
Country
United States
Zip Code
80523
Rhodes, Katherine A; Somprasong, Nawarat; Podnecky, Nicole L et al. (2018) Molecular determinants of Burkholderia pseudomallei BpeEF-OprC efflux pump expression. Microbiology 164:1156-1167
Webb, Jessica R; Price, Erin P; Somprasong, Nawarat et al. (2018) Development and validation of a triplex quantitative real-time PCR assay to detect efflux pump-mediated antibiotic resistance in Burkholderia pseudomallei. Future Microbiol 13:1403-1418
York, Joanne; Nunberg, Jack H (2018) A Cell-Cell Fusion Assay to Assess Arenavirus Envelope Glycoprotein Membrane-Fusion Activity. Methods Mol Biol 1604:157-167
Cummings, Jason E; Slayden, Richard A (2017) Transient In Vivo Resistance Mechanisms of Burkholderia pseudomallei to Ceftazidime and Molecular Markers for Monitoring Treatment Response. PLoS Negl Trop Dis 11:e0005209
Pettey, W B P; Carter, M E; Toth, D J A et al. (2017) Constructing Ebola transmission chains from West Africa and estimating model parameters using internet sources. Epidemiol Infect 145:1993-2002
Furuta, Yousuke; Komeno, Takashi; Nakamura, Takaaki (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 93:449-463
Skyberg, Jerod A; Lacey, Carolyn A (2017) Hematopoietic MyD88 and IL-18 are essential for IFN-?-dependent restriction of type A Francisella tularensis infection. J Leukoc Biol 102:1441-1450
Plumley, Brooke A; Martin, Kevin H; Borlee, Grace I et al. (2017) Thermoregulation of Biofilm Formation in Burkholderia pseudomallei Is Disrupted by Mutation of a Putative Diguanylate Cyclase. J Bacteriol 199:
Randall, Linnell B; Georgi, Enrico; Genzel, Gelimer H et al. (2017) Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance. J Antimicrob Chemother 72:1258-1260
Podnecky, Nicole L; Rhodes, Katherine A; Mima, Takehiko et al. (2017) Mechanisms of Resistance to Folate Pathway Inhibitors in Burkholderia pseudomallei: Deviation from the Norm. MBio 8:

Showing the most recent 10 out of 258 publications